IntraOp Medical

06/27/2023

Another step forward: The team at Dartmouth Cancer Center has selected IntraOp® Mobetron® with FLASH-IQ™ as their preferred platform for clinical research of FLASH radiotherapy in treating patients with skin lymphomas.*
Read the release:
https://cancer.dartmouth.edu/stories/article/flash-meets-mobetronr-advancing-radiation-therapy-cancer-research

(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.)

Radiation oncology boosts FLASH research studies to the next level.

05/12/2023

The exciting news from our partners at CHUV | Lausanne university hospital keeps coming! Based at Lausanne University Hospital and University of Lausanne in Switzerland, CHUV announced the first randomized Phase II selection trial of FLASH versus conventional radiotherapy for patients with localized carcinomas. This groundbreaking study is the second clinical human trial using Mobetron with electrons, signaling another significant impact on the future of cancer treatment.

Read the story:
https://intraop.com/news-events/second-clinical-human-trial-with-chuv-using-mobetron-with-flash-radiotherapy/


(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.)

First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinoma

05/11/2023

We're proud to announce the installation of the IntraOp® Mobetron® with FLASH-IQ™ at ten prestigious research facilities worldwide. This milestone represents IntraOp's unwavering commitment to advancing innovative cancer care technology and paving the way for the future of FLASH, as well as supporting ongoing research, development, and funding in the study of FLASH radiotherapy.*

Read the release:
https://intraop.com/news-events/tenth-flash-radiotherapy-mobetron-installation/

Are you attending ? Let’s meet and discuss what makes FLASH Radiotherapy such a promising modality when clinical treatment becomes a reality. Schedule a demo: https://contact.intraop.com/estro/?utm_source=fb&utm_medium=social&utm_campaign=estro-2023



(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.)

In Studies, The World’s Leading Cancer Centers Trust IntraOp Mobetron with Electrons

05/10/2023

IntraOp is excited to share the results for ultra-high dose rate FLASH radiotherapy survival and toxicity in independent murine studies by MD Anderson Cancer Center in Houston, TX, and CHUV | Lausanne university hospital in Lausanne, Switzerland, made possible by the IntraOp Mobetron with FLASH-IQ.*

This independent study also validates the robustness of the FLASH-IQ platform in reproducible FLASH effects. The study's findings suggest that "... using beam parameters that are known to evoke FLASH effects can lead to responses that are robust and reproducible across machines and institutions..." (Jean Bourhis et al.).

We are proud to support these seminal investigational studies with the stability, linearity, and reproducibility of IntraOp Mobetron with FLASH-IQ.


https://www.mdpi.com/2072-6694/15/7/2121

(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not currently cleared for sale by the US FDA.)

FLASH radiation therapy (RT) is a promising new paradigm in radiation oncology. However, a major question that remains is the robustness and reproducibility of the FLASH effect when different irradiators are used on animals or patients with different genetic backgrounds, diets, and microbiomes, all....

04/28/2023

Are you attending ESTRO this year?
We would welcome the opportunity to schedule an in-person demo, and a quick discussion about what makes FLASH Radiotherapy* such a promising modality when clinical treatment becomes a reality.

Schedule a demo here:
https://contact.intraop.com/estro/?utm_source=fb&utm_medium=social&utm_campaign=estro-2023

(*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.)

Are you attending ESTRO 2023 in Vienna? We would love to show you how the IntraOp Mobetron is the first and most advanced platform for delivering ultra-high dose rate radiotherapy with electrons.

03/19/2023

Come hear Dr. Brabham speak on Electron Therapy for the Precise and Non-Invasive Treatment of Nonmelanoma Skin Cancer. Join us at 12:15 pm CT in booth 222 and discover just how effective IntraOp Electron Therapy for Skin Cancer can be for both your practice and for your patients.

IntraOp is excited to join the American Academy of Dermatology for its AAD Annual Meeting in New Orleans, Louisiana on March 17-21, 2023.

03/18/2023

Join us for our Meet the Expert event tomorrow at 12:15 CT in booth 222. Dr. Jeffrey G. Brabham (MD, MBA) will be presenting on Electron Therapy for the Precise and Non-Invasive Treatment of Nonmelanoma Skin Cancer.

IntraOp is excited to join the American Academy of Dermatology for its AAD Annual Meeting in New Orleans, Louisiana on March 17-21, 2023.

03/17/2023

It’s finally here! And we have to say that it’s amazing to be in New Orleans for the 2023 AAD Annual Meeting. Come see us in booth 222.

03/06/2023

Has your practice considered offering a non-surgical complement to your Mohs program?

Electron Therapy is proven safe and effective for dermatology practices looking to increase patient capacity or provide non-invasive options for treating functionally sensitive areas.

https://contact.intraop.com/electron-therapy-skin-cancer-aad-2023/?utm_source=fb&utm_medium=org&utm_campaign=aad-2023

03/06/2023

Are you attending AAD? Be sure to catch the presentation by Dr. Jeffrey Brabham on Sunday. Details here:
https://contact.intraop.com/electron-therapy-skin-cancer-aad-2023/?utm_source=fb&utm_medium=org&utm_campaign=aad-2023

IntraOp is excited to join the American Academy of Dermatology for its AAD Annual Meeting in New Orleans, Louisiana on March 17-21, 2023.

01/18/2023

We proudly announce that Vanderbilt Health has treated their first pancreatic cancer patient using intraoperative radiation therapy (IORT) with electrons.

Read the full story here:
https://intraop.com/news-events/intraop-and-vmuc-announce-first-patient-treated-for-pancreatic-cancer-using-iort/

IntraOp and Vanderbilt University Medical Center Announce First Patient Treated for Pancreatic Cancer Using Intra-Operative Radiation Therapy With Electrons

11/23/2022

Interested in the future of FLASH radiotherapy?
Join us the day before FRPT as these leading institutions and Mobetron® with FLASH-IQ™ users, present their FLASH programs, ideas for clinical trials, and clinical translation:

→ The Ohio State University Comprehensive Cancer Center (OSU)
→ Centre Hospitalier Universitaire Vaudois (CHUV)
→ MD Anderson Cancer Center
→ Heidelberg University Hospital
→ Dartmouth-Hitchcock
→ Centre Hospitalier de l’Universite de Montreal (CHUM)
→ Institut Jules Bordet

If interested, register today. Space is almost full.

Please join us for a FLASH symposium and dinner the day before the FRPT conference. We will discuss the current revelations in FLASH research and the future monumental implications of FLASH Radiotherapy.